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Introduction
Aging is related both to an increased risk of Alzheimer’s 
disease (AD) and cancer, two life- threatening diseases. 
Several studies have reported a bidirectional inverse asso-
ciation between AD and cancer such that cancer risk was 
lower in AD patients [1–8] and vice versa [1, 2, 4, 5, 9, 
10]. Several biologic mechanisms have been hypothesized 
to underlie this inverse relationship between the two dis-
eases, including regulation of the cell cycle, with signaling 
pathways regulating cell death on one hand and prolifera-
tion on the other [11–13]. Molecular mechanisms have 
also been hypothesized; for example, the enzyme Pin1 
may be overactivated in many cancers and inactivated in 
AD brains [12, 14, 15]. Yet, whether previously observed 
associations reflect pathophysiologic processes rather than 
intrinsic limitations of epidemiologic studies remains 
uncertain.
An alternative explanation of the inverse association 
finding is ascertainment bias such that AD is less likely 
to be diagnosed in people with cancer, and cancer is less 
likely to be diagnosed in AD patients. There are special 
challenges in assessing the relationship between cancer 
ORIGINAL RESEARCH
Associations between cancer and Alzheimer’s disease in a 
U.S. Medicare population
Daryl Michal Freedman1, Jincao Wu1, Honglei Chen2, Ralph W. Kuncl3, Lindsey R. Enewold4,  
Eric A. Engels1, Neal D. Freedman1 & Ruth M. Pfeiffer1
1Department of Health and Human Services, National Institutes of Health, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
Rockville, Maryland
2Aging and Neuro-epidemiology Group, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, North Carolina
3Department of Biology, University of Redlands, Redlands, California
4Department of Health and Human Services, National Institutes of Health, Division of Cancer Control and Population Sciences, National Cancer 
Institute, Rockville, Maryland
© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, 
distribution and reproduction in any medium, provided the original work is properly cited.
Keywords
Alzheimer’s disease, Cancer, case-control, 
cohort
Correspondence
Daryl Michal Freedman, National Cancer 
Institute, Division of Cancer Epidemiology 
and Genetics, 9609 Medical Center Drive, 
7E538, Rockville, MD 20850. 
Tel: 240-276-7394; Fax: 240-276-7874; 
E-mail: freedmam@mail.nih.gov
Funding Information
This research was supported by the 
Intramural Research Program of the National 
Institutes of Health, National Cancer Institute, 
the National Institute of Environmental Health 
Sciences and the U.S. Public Health Service.
Received: 24 March 2016; Revised: 29 June 
2016; Accepted: 11 July 2016
Cancer Medicine 2016; 5(10):2965–2976
doi: 10.1002/cam4.850
Abstract
Several studies have reported bidirectional inverse associations between cancer 
and Alzheimer’s disease (AD). This study evaluates these relationships in a 
Medicare population. Using Surveillance, Epidemiology, and End Results (SEER) 
linked to Medicare data, 1992–2005, we evaluated cancer risks following AD in 
a case–control study of 836,947 cancer cases and 142,869 controls as well as 
AD risk after cancer in 742,809 cancer patients and a non- cancer group of 
420,518. We applied unconditional logistic regression to estimate odds ratios 
(ORs) and Cox proportional hazards models to estimate hazards ratios (HRs). 
We also evaluated cancer in relation to automobile injuries as a negative control 
to explore potential study biases. In the case–control analysis, cancer cases were 
less likely to have a prior diagnosis of AD than controls (OR = 0.86; 95% 
CI = 0.81–0.92). Cancer cases were also less likely than controls to have prior 
injuries from automobile accidents to the same degree (OR = 0.83; 95% 
CI = 0.78–0.88). In the prospective cohort, there was a lower risk observed in 
cancer survivors, HR = 0.87 (95% CI = 0.84–0.90). In contrast, there was no 
association between cancer diagnosis and subsequent automobile accident injuries 
(HR = 1.03; 95% CI = 0.98–1.07). That cancer risks were similarly reduced 
after both AD and automobile injuries suggest biases against detecting cancer 
in persons with unrelated medical conditions. The modestly lower AD risk in 
cancer survivors may reflect underdiagnosis of AD in those with a serious ill-
ness. This study does not support a relationship between cancer and AD.
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and AD, as both diseases may lead to physical disabilities 
and AD patients are cognitively impaired. Screening or 
even diagnostic tests for cancer may be diminished among 
those already compromised by cognitive impairment [16]. 
The intensity of medical surveillance could also influence 
diagnosis of cancer or AD. In addition, the relative rarity 
of combined cases of AD and specific cancers requires a 
large study population to examine associations by cancer 
site, including cancers which are often detected by 
screening.
To address these limitations and explore the relation-
ship between AD and overall cancer as well as with specific 
cancer sites, we used data from a large group of Medicare 
patients residing within the population- based Surveillance, 
Epidemiology and End- Results (SEER) Program registry 
areas. We examined the risk of incident cancer after an 
AD diagnosis, as well as the risk of a first AD diagnosis 
in cancer survivors, while controlling for frequency of 
physician visits, a surrogate for medical surveillance. We 
further used a group of patients with automobile injuries 
as a negative control because there is no apparent biologic 
relationship between automobile accidents and cancer 
diagnoses. This allowed us to explore biases in ascertain-
ing one serious medical condition in individuals already 
experiencing another.
Materials and Methods
Overview
We used data from Medicare, a federal health insurance 
system for the U.S. population aged ≥65 years, which 
had been linked to cancer data from the National Cancer 
Institute’s SEER program. SEER cancer registries cover 
about one- fourth of the U.S. population [17] and have 
a 98% cancer case ascertainment rate [18]. Medicare, 
which includes 97% of the age- eligible population, entitles 
beneficiaries to inpatient care (Part A), and 95% of those 
eligible subscribe to Part B, which covers physician and 
outpatient services [17].
The linked SEER and Medicare data provide demo-
graphic and clinical information on SEER cancer patients 
and their Medicare claims for services, including diagnostic 
codes [17]. The SEER- Medicare dataset al.so includes 
Medicare claims data on a 5% random beneficiary sample 
in SEER geographic areas. Thus, cancer cases and non- 
cases represent the age- eligible Medicare population in 
SEER areas [19].
Study design
We used the SEER- Medicare dataset for: (1) a case–control 
study to compute the odds of AD preceding cancer; and 
(2) a prospective cohort study of cancer survivors and a 
non- cancer comparison cohort and the subsequent risk 
of AD.
In the case–control study, cancer cases were patients 
in SEER who had been diagnosed with a first primary 
malignancy (1992–2005). To be included, cases had at 
least 13 months of Medicare coverage (outside of a health 
maintenance organization (HMO)) prior to cancer diag-
nosis (with full claim information, i.e., Parts A and B), 
to ensure a sufficient time period to identify AD before 
the cancer diagnosis. HMO coverage was not counted 
because Medicare does not obtain claims data for enrollees 
in HMOs [19]. Eligibility was restricted to those at least 
age 66 at diagnosis to permit the 13 months prior Medicare 
coverage, but less than age 85 because cancers (and AD) 
may be underascertained in the elderly due to comorbidi-
ties and short life expectancy [20]. Cases were not included 
if diagnoses were derived from autopsy or death certificate. 
Total cancer cases were N = 836,947 (Fig. 1).
Controls for the case–control analyses were selected 
from the 5% Medicare sample in SEER areas (1992–2005) 
and were age 66–84 years old at least some time during 
1992–2005, for a total of N = 604,719. Controls from 
this group were then frequency matched to cancer cases 
by sex, age category (5- year intervals), and calendar year 
of selection if they had at least 13 months of prior Part 
A/Part B/non- HMO Medicare coverage and no prior SEER- 
related cancer at the time of selection. For additional 
details on control selection see Engels et al. [19]. A total 
of 200,000 controls, which were sampled with replace-
ment, were frequency matched, corresponding to 
N = 142,869 individuals (Fig. 1).
For the cohort study of AD risk after cancer diagnosis, 
individuals with cancer were further restricted: first, cancer 
cases diagnosed between ages 84 and 85 were excluded 
to allow at least 1 year of follow- up after a cancer diag-
nosis to detect AD; and second, cases were excluded if 
they had been diagnosed with AD prior to study entry, 
yielding a total of N = 742,809 cancer cases in the cohort 
study (Fig. 1).
Similarly, subjects in the 5% random sample selected 
during the 1992–2005 period were eligible for inclusion 
in the non- cancer comparison group if at the time of 
selection, they were ages 66–84 years old, had ≥13 months 
of Medicare coverage (Parts A/B/no HMO), and had no 
cancer or AD prior to selection, N = 420,518 (Fig. 1). 
The selection date for this group was the earliest date 
that their eligibility criteria were met.
In both the case–control and cohort studies, cancer 
sites were classified based on the SEER “site recode with 
Kaposi sarcoma and mesothelioma” variable according to 
International Classification of Diseases for Oncology (third 
edition, ICD- O- 3). In addition to overall cancer and 
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specific cancer sites, we grouped cancer sites into smoking- 
related and non- smoking- related cancers because at least 
one study suggested the relationship between AD and 
cancer differed between smoking- and non- smoking- related 
cancers in that AD risk was lower in survivors of smoking- 
related cancers [5]. Smoking- related cancer sites include 
cancers of the oral cavity and pharynx, lip, pancreas, lung/
bronchus, larynx, cervix, kidney/renal pelvis, bladder, 
esophagus, and stomach;[21] all other sites were catego-
rized as non- smoking- related cancers.
AD was based on ICD- 9 code 331.0 in Medicare claims. 
We classified a person as having been diagnosed with 
AD if there was one hospital or two physician/outpatient 
AD claims at least 30 days apart (because hospital claims 
are more thoroughly audited), a method for ascertaining 
disease similar to that used for previous SEER- Medicare 
studies of other medical conditions [19, 22].
Statistical analyses
Case–control study of cancer after AD
We estimated odds ratios (ORs) and 95% confidence 
intervals (CIs) for the association of AD with cancer risk 
in cancer cases and controls using unconditional logistic 
regression models. We accounted for repeated selection 
of controls in the variance calculation [19].
Cohort study of AD after cancer
In the prospective cohort analysis, we compared AD inci-
dence in cancer cases and cancer- free individuals (com-
parison group). For the cancer cases, follow- up began at 
the age at cancer diagnosis, and for the comparison group, 
at the age at selection. Follow- up ended at the earliest 
age of AD diagnosis, discontinuation of Part B Medicare 
coverage, transfer to an HMO, death, diagnosis of a cancer 
(for the comparison group), attaining age 85 or December 
31, 2005. With age as the time scale, we used Cox pro-
portional hazards models to assess hazard ratios (HRs) 
and 95% CIs of association of AD with cancer status. 
We accounted for left truncation due to late age at entry 
using the entrytime statement in proc phreg, SAS 9.2.
Common elements to both designs and analyses
We adjusted all models for major demographic charac-
teristics: sex, race/ethnicity (white, black, Asian- American, 
Hispanic American, Native American, other), age (used 
as the timescale in the cohort models; in five- year groups 
Figure 1. Flowchart of cancer case and non- cancer groups.
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in the case–control models), cancer registry (because back-
ground incidences varied), and frequency of physician 
visits, as described below. For cohort models the baseline 
hazard was stratified on birth year (to account for secular 
trends), and case–control analyses were additionally 
adjusted for calendar year of cancer diagnosis/control 
selection (1992- 94, 1995–1998, 1999–2005), one of the 
matching criteria.
The first AD claim date was considered the date of 
AD diagnosis. AD risks were analyzed across several time 
intervals. In the case–control design, the intervals were 
<1 year; 1–<5 years; and 0–<5 years prior to cancer 
because Medicare claims were only available for up to 
5 years for some participants. In the cohort models, the 
intervals were: <1 year; 1–<5 years; 5–<10 years; and 
0–<10 years after cancer. Because patients with AD or 
cancer are often subject to heightened medical surveil-
lance, we adjusted for frequency of physician visits, exclud-
ing claims by physicians who had limited responsibility 
for direct patient care, that is, radiologists, anesthesiologists, 
pathologists. In the case–control analyses, we adjusted for 
the average number of visits across all intervals (excluding 
the first and last). In the cohort analyses, physician visits, 
a maximum of one per day, were counted during 6- month 
intervals between the selection and censor dates, excluding 
the first and last intervals. Physician visits were categorized 
as 0, 1–5, 6–10, >10 times during each 6- month 
interval.
We assessed associations stratified by sex, race/ethnicity, 
and age at time of selection (66–<70; 70–<79; 
80–<85 years); we also examined associations separately 
for specific cancer sites and whether the cancer was 
smoking- related. We limited cancer site- specific analyses 
(in both designs) to sites with at least 20 AD cases in 
the cohort analysis.
We also included analyses with all covariates other than 
number of physician visits and by cancer stage for several 
cancer sites.
We applied a Bonferroni correction to account for 
multiple comparisons when interpreting all the subgroups 
and site- specific cancers for the total follow- up period in 
the case–control and cohort analysis (n = 28 comparisons 
in each study design). This resulted in a P- value of 
P < 0.0018. P- values were based on two- sided tests.
Studies of cancer associated with automobile 
accident injuries
To evaluate potential ascertainment biases in evaluating 
the relationships between cancer and AD, we used auto-
mobile accident injuries (ICD- 9 E810- 819) as negative 
controls and conducted parallel analyses on cancer and 
automobile injuries. In the analysis, we simply substituted 
automobile accident injuries for AD in both case–control 
and cohort analyses. We expected the associations to be 
null for both designs because there is no plausible hypoth-
esis biologically relating injuries due to automobile acci-
dents and cancer. We also chose automobile accidents as 
negative controls because, like AD, a reasonable proportion 
are sufficiently severe [23] as to potentially impact the 
frequency of cancer screening/workups; accident numbers 
are large enough to allow comparisons between those with 
AD and those without AD; and there is no etiologic 
overlap between accidents and AD. Due to the acute nature 
of automobile injuries, claims for automobile accident 
injuries were based on a single medical visit (hospitaliza-
tion or medical visit). In cohort analyses of cancer fol-
lowed by automobile accident injuries, individuals were 
excluded if they had prior automobile accident injuries 
because multiple accidents may indicate a common under-
lying cause [24]. Otherwise, the analyses were based on 
the models for cancer and AD.
All analyses were conducted in SAS (Version 9.2, SAS 
Institute, Inc., Cary, NC). This study was exempted by 
NIH’s Office of Human Subjects Research from 
Institutional Review Board approval.
Results
Case–control analysis of Alzheimer’s disease 
prior to cancer diagnosis
There were 836,947 cancer cases and 200,000 frequency- 
matched controls in the case–control analysis of cancer 
after AD (Table 1). Both cancer cases and controls had 
a median age of 74 at diagnosis/selection and were similar 
across the matching variables (age, sex, selection year), 
as well as by race/ethnicity. In the 5 years preceding the 
cancer diagnoses or control selections, there were 5961 
diagnoses of AD in cancer cases and 1360 in controls 
(Table 2).
Overall, cancer cases were less likely to have a prior 
AD diagnosis compared to controls (OR = 0.86, 95% 
CI = 0.81–0.92) (Table 2). The lower risk was slightly 
more evident in men than in women (OR = 0.81 vs. 
0.90, respectively), and was largely limited to whites and 
participants older than age 70. Further, the inverse asso-
ciation with AD was more evident for non- smoking- related 
cancers than smoking- related cancers. Adjusting for doc-
tors’ visits attenuated the odds ratios. (Table S1). For all 
analyses mentioned above, the inverse association with 
cancer was more evident for AD identified 1–5 years before 
cancer diagnosis than AD identified in the year immedi-
ately before cancer diagnosis. When the 19 specific cancer 
sites were examined, only breast cancer (OR = 0.77), 
uterine cancer (OR = 0.64), and prostate cancer 
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(OR = 0.52) were statistically significantly related to a 
lower odds of having a previous AD diagnosis after a 
Bonferroni correction (Table 2).
We also examined both the ORs for local and distant 
(late stage) cancer for four common cancers and did not 
find noticeable differences in associations for cancers of 
the breast, colon, and lung. Table S2. For prostate cancer, 
however, the risks were substantially lower for local/regional 
versus distant stage cancer, OR = 0.48; 95% CI = 0.41–0.55; 
versus OR = 0.68; 95% CI = 0.50–0.93, respectively.
In the analysis using automobile accidents as a negative 
control group, we found an inverse association between 
automobile accidents and subsequent cancer risk 
(OR = 0.83; 95% CI = 0.78–0.88); similar to that observed 
for AD and risk of subsequent cancer (Table 3), as well 
as inverse associations between automobile accidents and 
prostate cancer (OR = 0.81 (95% CI = 0.72–0.91) and 
breast cancer (0.86; 95% CI = 0.75–0.97).
Prospective cohort analysis of Alzheimer’s 
disease following cancer diagnosis
The prospective cohort analysis included 742,809 cancer 
cases and 420,518 controls at baseline and 11,812 cancer 
cases and 9714 controls were later identified as having 
AD within 10 years of follow- up (Table 4). The cancer 
cases were more likely to be older, male and selected in 
later calendar periods, but the race/ethnicity distribution 
was similar in those with cancer and the comparison 
group. For cancer cases, there were 2.1 million person- 
years of follow- up (median 1.9 years) and for the non- 
cancer comparison group, 2.4 million person- years (median 
5.8 years).
Overall, there was a slight statistically significant lower 
risk of AD in cancer cases than in the comparison group, 
HR = 0.87; 95% CI = 0.84–0.90 (Table 5). The inverse 
association was slightly stronger in women than in men; 
and similar to the case–control analysis of AD prior to 
cancer, the inverse association was largely limited to whites 
and older age groups. When smoking- related cancers and 
non- smoking- related cancers were analyzed separately, the 
inverse association was more evident for non- smoking- 
related cancers. Before adjusting for the frequency of 
doctors’ visits, the HRs were more attenuated. Across all 
these analyses, we identified a consistent U- shaped pattern 
of the temporal relationship of the association of AD 
with cancer: the HR was close to 1 in the first year fol-
lowing cancer diagnosis, fell to its lowest level in years 
1–5 and then rose somewhat, but mostly retained statistical 
significance, 5–10 after cancer diagnosis.
Of the 19 specific cancer sites assessed for AD risk 
after cancer, only six cancer sites were statistically sig-
nificantly and inversely related to AD, after correction 
for multiple comparisons: the HRs ranged from 0.58 for 
ovarian cancer to 0.90 for prostate cancer and included 
rectal, breast, and uterine cancers and leukemia (Table 5). 
With the exception of cervical cancer, the HRs were smaller 
than 1.00 for all other cancer sites.
Unlike our analysis for cancers prior to AD diagnosis, 
there was no relationship between cancer and risk of 
subsequent injuries due to automobile accidents 
(HR = 1.03; 95% CI = 0.98–1.07) (Table 3).
Discussion
In this large, population- based SEER- Medicare study, we 
found that the risk of cancer was 14% lower in AD patients 
and comparable to the cancer risk reduction after auto-
mobile accident injuries. The risk of AD was also 13% 
lower in cancer patients. In both analyses, the inverse 
association was largely limited to whites and participants 
older than age 70.
Comparison with other studies
Several other studies have reported lower risks of AD 
diagnosis before and after overall cancer diagnosis [1–4, 
6, 7, 10, 25] or for particular cancer sites [6, 9]. The 
findings for subpopulations, however, vary across studies. 
An inverse association between AD and cancer was not 
Table 1. Characteristics of cancer cases and controls in retrospective 
case–control analysis of Alzheimer’s disease prior to cancer
 Cancer cases 
(N = 836,947)
Control Group 
(N = 142,869)
Age1 in years, n(%)
66–<70 27.0% 27.9%
70–<80 55.2% 54.7%
80–<85 17.9% 17.4%
Median age 74 74
Sex, n(%)
Male 54.5% 54.8%
Female 45.5% 45.2%
Selection year, n(%)
1992–1994 17.4% 17.2%
1995–1998 20.2% 20.0%
1999–2005 62.4% 62.8%
Race/ethnicity, n(%)
White 86.1% 84.3%
Non- white 13.9% 15.7%
Black 7.8% 6.7%
Asian 2.5% 3.9%
Hispanic 1.4% 2.4%
Native American Indian 0.2% 0.4%
Other/unknown 2.0% 2.3%
1For cancer cases, age is based on age at cancer diagnosis; for controls, 
age is based on age at selection as a control.
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found in men in Ou et al.;[3] in blacks in Roe et al. 
[2]. (where in fact a positive association was noted); or 
in those <60 years in Ou et al. [3]. and <65 years in 
Musicco et al. [4]. Moreover, several studies did not find 
any association between AD and total cancer [9], includ-
ing an autopsy study [26].
A key issue in observational epidemiologic studies of 
the relationship between AD and cancer is whether the 
Table 2. Odds ratio (OR) for Alzheimer’s disease (AD) in cancer cases compared to non- cancer controls, 1992–20051
 <1 year prior to cancer 1–<5 years prior to cancer 0–<5 years prior to cancer
OR 95% CI OR 95% CI Control2
(n)
Case2
(n)
OR 95% CI
Overall 0.95 0.85–1.05 0.81 0.75–0.88 1369 5961 0.86 0.81–0.92
Sex
Men 0.91 0.78–1.06 0.74 0.65–0.84 586 2544 0.81 0.73–0.909
Women 0.98 0.86–1.12 0.85 0.77–0.94 783 3417 0.90 0.82–0.98
Race
White 0.94 0.84–1.04 0.80 0.73–0.87 1136 4888 0.85 0.79–0.919
Non- white 1.03 0.82–1.29 0.87 0.71–1.06 233 1073 0.94 0.80–1.10
Age groups (years)
66–<70 1.06 0.70–1.59 0.90 0.61–1.31 63 299 0.96 0.72–1.28
70–<80 0.97 0.85–1.12 0.80 0.71–0.89 660 2969 0.87 0.79–0.95
80–<85 0.90 0.78–1.04 0.79 0.71–0.89 646 2693 0.84 0.76–0.929
Smoking- related cancers3 1.04 0.92–1.68 0.88 0.80–0.97 1369 2092 0.95 0.88–1.02
Non- smoking- related cancers4 0.91 0.82–1.01 0.77 0.71–0.84 1369 3869 0.83 0.77–0.899
Individual cancer sites
Oral cavity5 0.88 0.59–1.31 1.07 0.81–1.41 1369 74 0.96 0.75–1.22
Esophageal 0.84 0.55–1.29 0.89 0.64–1.23 1369 61 0.88 0.68–1.14
Stomach 1.24 0.96–1.61 1.23 1.00–1.51 1369 174 1.24 1.05–1.46
Small intestine 1.38 0.80–2.41 1.27 0.78–2.05 1369 30 1.31 0.90–1.89
Colon 1.03 0.90–1.23 0.89 0.79–1.00 1369 747 0.95 0.86–1.04
Rectum6 1.02 0.81–1.27 0.75 0.62–0.91 1369 204 0.84 0.72–0.98
Pancreas 1.28 1.04–1.59 1.01 0.83–1.23 1369 228 1.11 0.95–1.29
Larynx 0.52 0.26–1.01 0.55 0.32–0.93 1369 22 0.52 0.34–0.80
Lung and bronchus 1.01 0.89–1.15 0.84 0.75–0.94 1369 1036 0.91 0.84–0.91
Melanoma7 0.75 0.55–1.03 0.93 0.75–1.15 1136 134 0.85 0.71–1.03
Breast (female) 0.75 0.63–0.89 0.79 0.64–0.89 783 686 0.77 0.69–0.859
Cervix 1.07 0.60–1.90 1.05 0.67–1.64 783 33 1.09 0.76–1.56
Uterus8 0.79 0.59–1.07 0.55 0.42–0.71 783 111 0.64 0.52–0.789
Ovary 0.93 0.66–1.31 0.78 0.59–1.04 783 91 0.85 0.68–1.06
Prostate 0.65 0.54–0.78 0.44 0.38–0.52 586 555 0.52 0.46–0.599
Bladder 1.06 0.87–1.30 0.95 0.80–1.12 1369 341 0.99 0.87–1.13
Kidney/renal pelvis 1.05 0.79–1.39 0.61 0.46–0.81 1369 111 0.78 0.64–0.96
Thyroid 0.57 0.26–1.21 0.63 0.34–1.14 1369 17 0.58 0.36–0.94
Leukemia 1.28 1.01–1.61 1.01 0.82–1.24 1369 195 1.11 0.95–1.30
1Models have been adjusted for age, race, sex, number of doctors’ visits, cancer registry area, and selection years, except that sex was not adjusted 
for in the subpopulation based on sex, nor race, in the subpopulation defined by race. There were a total of 836,947 cancer patients and 200,000 
persons in the comparison population. Data source is SEER- Medicare. Cancer cases were classified using the “SEER site recode with Kaposi sarcoma 
and mesothelioma.” Refer to http://seer.cancer.gov and for details, see site recode ICD- O- 3.
2Number of AD cases.
3Smoking- related cancers include oral cavity and pharynx, lip, pancreas, lung and bronchus, larynx, cervix, kidney and renal pelvis, bladder, esopha-
gus, and stomach.
4Non- smoking- related cancers include all cancers other than smoking- related cancers.
5Includes tongue, floor of mouth, gum and mouth, tonsil, oropharynx, hypopharynx.
6Includes rectum and rectosigmoid junction.
7Only whites.
8Includes corpus uterine and uterus, not otherwise specified.
9P- values for the associations between the groups (e.g., men) and specific cancer sites with PD (for 0 < 10 years) that were statistically significant after 
multiple comparison corrections (n = 28 comparisons) at a level of P < 0.0018).
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observed reduced risks stem from biological factors or 
whether instead they reflect biases such as a lower ascer-
tainment of cancers or AD in elderly individuals who 
already have a serious illness.
Several previous epidemiologic studies of the associa-
tion recognize the potential impact of ascertainment bias 
in cognitively impaired persons [3, 6, 26, 27]. Patients 
with dementia present difficult issues of communication 
and consent to testing, and may be frightened by blood 
draws or other screening/diagnostic interventions [28]. 
For example, Heflin et al. found that cancer screening 
was less common in older persons with cognitive impair-
ments or physical injuries [16]. Also, analysis of SEER- 
Medicare data showed that patients with AD were often 
diagnosed with cancers at more advanced stages [29], 
which suggests less screening and delayed comprehensive 
clinical evaluation. In our analyses of common cancers, 
we found similarly reduced risks of both local and distant 
cancers, although we did find markedly lower risk of 
local/regional than distant prostate cancer in AD patients 
compared to people without AD, which is consistent 
with reduced routine screening for prostate cancer after 
AD.
Our analysis of cancer ascertainment after automobile 
accidents supports a bias in ascertaining cancer diagnoses 
after AD or other serious medical conditions. We used 
automobile accident injuries as a negative control outcome 
because there is no known biological relationship between 
cancer and automobile injuries. In this analysis, we found 
that cancers were diagnosed at lower rates after AD to 
a similar degree as cancer after automobile accident inju-
ries. The comparison of effect estimates of cancer risk 
after AD an after auto accidents is informative because 
health care systems may vary in the assiduousness with 
which they screen or work- up those who are physically 
or mentally debilitated.
Table 3. Relationship between cancer before and after injuries due to automobile accidents
HRs of injuries due to automobile accidents after cancer1
 
<1 year follow- up
1–<5 years 
follow- up
5–<10 years 
follow- up
0–<10 years follow- up 
Automobile Accident Injury Cases
HR 95% CI HR 95% CI HR 95% CI Comparison group3 Cancer patients3 HR 95% CI
Overall 1.08 0.91–1.27 0.96 0.89–1.04 0.97 0.88–1.08 6746 6236 1.03 0.98–1.07
ORs of prior injuries due to automobile accidents in cancer cases compared to non- cancer controls2
 <1 year prior to cancer 1–<5 years prior to cancer 0–<5 years prior to cancer
OR 95% CI OR 95% CI Controls3 Cancer Cases3 OR 95% CI
Overall 0.86 0.76–0.96 0.81 0.76–0.87 1519 8403 0.83 0.78–0.88
ORs, odds ratios.
1Models have been adjusted for race, sex, and number of doctors’ visits, stratified on birth year and cancer registry area. The study populations of the 
cancer cohort and comparison cohort both excluded subjects with claims prior to baseline for auto accidents based on Medicare claims. Data source 
is SEER- Medicare.
2Models have been adjusted for age, race, sex, number of doctors’ visits, cancer registry area, and selection years. Data source is SEER- Medicare.
3Number of cancer cases or patients/controls or comparison group with automobile accident injuries.
Table 4. Characteristics of cancer cases and non- cancer comparison 
group in prospective cohort analysis of Alzheimer’s disease in cancer 
survivors
 Cancer cases 
(N = 742,809)
Comparison Group 
(N = 420,518)
Age1 in years, n(%)
66–<70 23.2% 64.7%
70–<80 59.9% 29.6%
80–<85 16.9% 5.7%
Median age 74 67
Sex, n (%)
Male 55.4% 41.6%
Female 44.6% 58.4%
Selection year, n (%)
1992–1994 17.8% 57.9%
1995–1998 20.3% 14.9%
1999–2005 61.9% 27.2%
Race/ethnicity, n(%)
White 86.1% 83.7%
Non- white 13.9% 16.3%
Black 7.7% 7.6%
Asian 2.5% 3.5%
Hispanic 1.4% 2.3%
Native American Indian 0.2% 0.3%
Other/unknown 2.0% 2.6%
Person- year 2,108,469 2,435,651
Median follow- up (yrs.) 1.9 5.8
1For cancer cases, age is based on age at cancer diagnosis; for compari-
son group, age is based on age at selection for the comparison group.
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Table 5. Hazards Ratio (HR) for Alzheimer’s disease (AD) after first primary cancer diagnosis, 1992–20051
<1 year follow- up 1–<5 year follow- up 5–<10 year 
follow- up
0–<10 year follow- up
HR 95% CI HR 95% CI HR 95% CI Control2
(n)
Case2
(n)
HR 95% CI
Overall 0.99 0.84–1.17 0.77 0.72–0.83 0.89 0.84–0.95 9714 11812 0.87 0.84–0.90
Sex
Men 1.02 0.80–1.29 0.79 0.72–0.88 0.83 0.76–0.92 3126 6350 0.90 0.85–0.959
Women 0.96 0.76–1.21 0.75 0.68–0.82 0.94 0.86–1.03 6588 5462 0.84 0.80–0.889
Race
White 0.97 0.81–1.17 0.75 0.70–0.81 0.90 0.84–0.97 8160 10081 0.86 0.83–0.899
Non- white 1.35 0.98–1.85 0.94 0.81–1.10 0.90 0.77–1.06 1554 1731 0.96 0.88–1.04
Age at cancer diagnosis, (years)
66–<70 1.25 0.91–1.71 0.70 0.61–0.80 0.96 0.86–1.08 3665 1338 0.90 0.84–0.97
70–<80 0.87 0.70–1.09 0.79 0.72–0.86 0.87 0.81–0.94 8389 8193 0.87 0.83–0.909
80–<84 1.05 0.75–1.49 0.78 0.66–0.91 – – 3584 2281 0.85 0.79–0.919
Smoking- related 
cancers3
1.14 0.91–1.41 0.83 0.74–0.93 0.91 0.80–1.03 9714 2286 0.91 0.86–0.969
Non- smoking- related 
cancers4
0.97 0.81–1.16 0.77 0.71–0.82 0.90 0.84–0.96 9714 9526 0.86 0.83–0.899
Individual cancer sites
Oral cavity5 1.30 0.83–2.05 0.65 0.47–0.91 0.63 0.38–1.05 9714 105 0.83 0.68–1.01
Esophageal 1.26 0.74–2.17 0.69 0.40–1.20 0.43 0.11–1.72 9714 44 0.93 0.69–1.26
Stomach 0.91 0.53–1.55 0.83 0.60–1.16 0.98 0.60–1.58 9714 100 0.83 0.67–1.02
Small intestine 0.57 0.21–1.60 0.78 0.46–1.35 0.47 0.15–1.47 9714 25 0.68 0.46–1.02
Colon 1.23 0.94–1.61 0.85 0.74–0.97 0.92 0.79–1.07 9714 1256 0.92 0.86–0.99
Rectum6 1.16 0.82–1.66 0.55 0.44–0.69 0.93 0.73–1.18 9714 370 0.79 0.71–0.899
Pancreas 0.66 0.39–1.11 0.35 0.17–0.72 0.53 0.13–2.18 9714 45 0.68 0.50–0.92
Larynx 0.61 0.29–1.27 0.68 0.47–0.97 0.74 0.45–1.20 9714 73 0.72 0.57–0.92
Lung and bronchus 1.10 0.84–1.44 0.88 0.75–1.03 0.96 0.77–1.20 9714 791 0.96 0.88–1.04
Melanoma7 0.79 0.49–1.26 0.76 0.60–0.96 0.89 0.68–1.17 8160 303 0.82 0.71–0.93
Breast (female) 0.84 0.62–1.13 0.77 0.68–0.87 0.98 0.87–1.10 6588 2187 0.88 0.83–0.949
Cervix 1.94 0.85–3.93 1.01 0.65–1.57 1.25 0.70–2.21 6588 64 1.30 1.00–1.69
Uterus8 1.04 0.68–1.58 0.63 0.50–0.78 0.84 0.67–1.05 6588 385 0.80 0.71–0.909
Ovary 0.60 0.32–1.12 0.31 0.21–0.47 1.19 0.77–1.81 6588 89 0.58 0.46–0.729
Prostate 0.92 0.62–1.22 0.83 0.74–0.93 0.86 0.77–0.96 3126 3574 0.90 0.85–0.969
Urinary bladder 1.09 0.79–1.49 0.88 0.75–1.03 0.95 0.79–1.14 9714 779 0.97 0.89–1.06
Kidney/renal 1.27 0.85–1.89 0.79 0.62–1.00 0.84 0.61–1.14 9714 243 0.83 0.72–0.96
Thyroid 0.69 0.34–1.41 0.56 0.36–0.86 0.87 051–1.46 9717 57 0.71 0.54–0.94
Leukemia 0.79 0.50–1.26 0.64 0.48–0.84 0.71 0.48–1.05 9714 163 0.72 0.61–0.859
1Models have been adjusted for race, sex and number of doctors’ visits, stratified on birth year and cancer registry area, except that sex was not ad-
justed for in the subpopulation based on sex, nor race, in the subpopulation defined by race. There were a total of 742,809 cancer patients and 
420,518 persons in the comparison population. Data source is SEER- Medicare. Cancers were classified using the “SEER site recode with Kaposi sar-
coma and mesothelioma.” Refer to http://seer.cancer.gov and for details, see site recode ICD- O- 3.
2Number of AD cases.
3Smoking- related cancers include oral cavity and pharynx, lip, pancreas, lung and bronchus, larynx, cervix, kidney and renal pelvis, bladder, esopha-
gus, and stomach.
4Non- smoking- related cancers include all cancers other than smoking- related cancers.
5Includes tongue, floor of mouth, gum and mouth, tonsil, oropharynx, hypopharynx.
6Includes rectum and rectosigmoid junction.
7Only whites.
8Includes corpus uterine and uterus, not otherwise specified.
9P- values for the associations between the groups (e.g., men) and specific cancer sites with PD (for 0 < 10 years) that were statistically significant after 
multiple comparison corrections (n = 28 comparisons) at a level of P < 0.0018).
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Moreover, the few studies that simultaneously examined 
the AD/cancer relationship in both directions often found 
lower [2, 4], sometimes substantially lower [5] risks in 
the analysis of cancer following AD than in the analysis 
of AD following cancer diagnosis. This further suggests 
factors other than common biologic mechanisms contrib-
uting to fewer cancers being diagnosed after AD. In addi-
tion, in our analysis of specific cancer sites, we found a 
similar pattern, particularly for cancers that are often 
detected by screening. For example, the OR for breast 
cancer following AD was 0.77 compared to 0.88 for AD 
following a breast cancer diagnosis, and corresponding 
risk estimates for prostate cancer was 0.52 and 0.90, 
respectively. Finally, we also found that the inverse asso-
ciation was stronger in older age groups compared to 
younger age groups, which is also consistent with ascer-
tainment bias being more pronounced in the elderly who 
tend to have more disabilities.
Akushevich et al. [6]. who evaluated AD in relation 
to some cancer sites in SEER- Medicare (using different 
design criteria than ours) also found some significant 
inverse relationships but only when AD preceded cancer. 
While Akushevich et al. acknowledge possible biases in 
diagnosing cancer after AD, they argue that bias cannot 
fully account for the reduced risks because risks of other 
diseases, specifically myocardial infarction, renal disease, 
and ulcer, were not reduced after AD. However, the more 
acute symptoms associated with these conditions may 
make them less prone to ascertainment bias.
The inverse risks we observed for cancer after AD were 
also more modest than those reported by most other 
studies [1, 2, 4, 5], which saw up to 69% reduced risks 
[2]. Contributing to these lower risks may be the reliance 
on self- report, including postal survey;[1, 5] hospitaliza-
tion records [2] (rather than both inpatient and outpatient 
visit data); or caregiver reports [10] for cancer diagnoses, 
whereas the SEER/Medicare dataset uses diagnoses from 
cancer registries with 98% complete cancer 
ascertainment.
We also observed a slightly (13%) lower AD risk after 
a cancer diagnosis, whereas automobile accident injuries 
were not related to a previous cancer diagnosis. The lack 
of an automobile accident/cancer relationship is consistent 
with our expectations that there is no biologic relation-
ship between the two conditions. Yamauchi et al. also 
found no relationship between cancer and subsequent 
externally caused injury deaths in those ≥65 years [30]. 
Moreover, automobile injuries are likely to be detected 
whether or not a person has cancer and therefore are 
not expected to be associated with a prior cancer diag-
nosis. In contrast to automobile injuries, AD is a progres-
sive chronic condition, which is often diagnosed after 
subjective memory complaints and comprehensive 
neuropsychological evaluations [31]. Thus, cancer patients 
who are already confronting a life- threatening condition 
may be less likely to be worked up for less life- threatening 
conditions. Careful analysis of subpopulations may further 
help to evaluate potential ascertainment bias of AD in 
cancer survivors. As noted, the lower risk was attenuated 
in those <70 years. Similarly, Musico et al. [4]. found 
no lower risk in those under age 65, as would be expected 
if medical evaluations for AD diagnosis were more likely 
in younger cancer survivors. We also observed no associa-
tion in blacks and in fact risk was substantially elevated 
in Roe et al. [2], the only other study to examine risk 
by race. Health professionals may be more likely to diag-
nose AD in blacks once they are being seen for other 
medical concerns under the assumption that blacks are 
disproportionately burdened by AD [32]. This seems to 
be a more plausible explanation for observed racial dif-
ferences than true biological variation by race in the 
relationship between cancer and AD. On balance, therefore, 
these findings provide limited support for a biologic expla-
nation for the reduced risk of AD following a cancer 
diagnosis.
Strengths and limitations of the study
A key strength of this study is its large size, with more 
than 700,000 cancer cases and nearly 5 million person- 
years in the cohort analysis. Whereas even the largest 
previous studies had less than a few hundred subjects 
diagnosed with both cancer and AD [4, 5], our study 
had nearly 12,000 cancer survivors later diagnosed with 
AD and nearly 6000 cancer cases who had been diagnosed 
with AD before their cancer diagnosis. Large numbers 
permitted us to assess associations with AD for specific 
cancer sites and for subgroups defined by race, sex, and 
age. As a population- based U.S. study, this is one of only 
two studies that have evaluated associations by race/eth-
nicity [2]. Because it is hypothesized that underlying 
biologic mechanisms contribute to an inverse relationship 
between cancer and AD, regardless of disease order, it is 
important to evaluate risks bidirectionally.
Another strength of our study is the analysis of the 
relationship between automobile accident injuries and 
cancer, which served as a comparison for evaluating poten-
tial biases in the AD/cancer relationship. Other strengths 
include the comprehensive ascertainment of SEER cancers; 
the availability of outpatient and inpatient data to identify 
incident AD; physician visit frequency data to control for 
surveillance intensity; and nationwide- claims data for AD, 
which substantially mitigates losses due to migration.
Limitations of the study include the fact that Medicare 
studies rely on claims data, rather than validated clinical 
diagnoses, which could lead to underascertainment and 
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misclassification of AD, as well as potentially incorrect 
assignment of dates of diagnosis. However, a study of 
Medicare claims data found that nearly 80% of AD patients 
were identified as having AD based on 5 years of claims 
data [33], although another study using a single year of 
claims found a much lower sensitivity (<40%) [34]. To 
reduce misclassification, we identified AD cases based on 
both inpatient claims, which are well- audited, and multiple 
outpatient/physician claims. Misclassification biases could 
be differential (e.g., more misclassification of, say, AD as 
depression among cancer survivors, which would artificially 
reduce risks) and/or nondifferential, which would bias 
toward the null. We also assumed that deaths due to 
conditions other than AD were independent of AD risks 
for those with cancer and those without cancer. Survival 
analysis, however, assumes this type of conditionally inde-
pendent censoring.
Other limitations include the necessary restriction to 
Medicare- age eligible individuals (age ≥66 years); yet, 
because both cancer and especially AD [35] are diseases 
of aging, most people with both conditions likely age- 
qualify for Medicare. Also, Medicare data also lack lifestyle 
information, but smoking, which is most strongly related 
to cancer, remains of uncertain relationship with AD 
[35–37]. In addition, our models did not account for 
treatment effects, which could potentially confound the 
relationship between the two diseases [13]. Particular 
chemotherapeutic agents for site- specific cancers have been 
linked to both neurotoxic and neuroprotective effects [13]. 
As noted, it is also possible that some individuals with 
AD are misdiagnosed with depression [38]. In contrast, 
other studies in Medicare have observed no relationship 
between cancer and subsequent amyotrophic lateral scle-
rosis [39] or Parkinson’s disease [40], both diseases that 
have more clinically visible motor symptoms. Finally, our 
study’s generalizability could have been affected by our 
exclusion of HMO subscribers, but this seems unlikely 
since <14% persons enrolled in HMOs during most of 
the study period (1996–2005), and race/age differences 
between the HMO and non- HMO populations were small 
[41].
Conclusions and future work
Although we found a modest inverse association between 
cancer and AD, the totality of the evidence supports 
ascertainment bias or diagnostic misclassification as an 
explanation for this epidemiologic observation. Therefore, 
this comprehensive analysis provided limited support for 
a true biologic relationship between cancer and AD. Future 
epidemiologic studies of the relationship between cancer 
and AD should carefully account for biases affecting iden-
tification of cancer and AD cases.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Table S1. Relationship between cancer diagnosis before 
and after Alzheimer’s disease (AD), adjusting for multiple 
variables,a excluding frequency of doctors’ visits
Table S2. Odds ratios (ORs) for Alzheimer’s disease 
(AD) prior to first primary cancer diagnosis, 1992- 2005, 
stratified by local1 and distant stage for selected 
cancers.2
